trending Market Intelligence /marketintelligence/en/news-insights/trending/pwot0hy3kbototehzte3wa2 content esgSubNav
In This List

Spring Bank Pharmaceuticals prices common stock offering


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises

Spring Bank Pharmaceuticals prices common stock offering

Spring Bank Pharmaceuticals Inc. priced an underwritten public offering of 3 million common shares at $12.50 each.

The Hopkinton, Mass.-based biopharmaceutical company expects to raise gross proceeds of $37.5 million.

Underwriters have a 30-day option to buy up to 450,000 additional common shares at the offering price.

Spring Bank expects the offering, which is subject to customary closing conditions, to close on or about Aug. 13.

Net proceeds will be used on clinical trials, nonclinical studies, research and development as well as general corporate purposes.

Jefferies and Piper Jaffray are acting as joint book-running managers for the offering.